Prestige Consumer Healthcare's stock experienced a sharp intraday plummet of 16.04% on Thursday, reflecting significant negative investor sentiment.

The movement appears to be primarily driven by a key analyst action, as Oppenheimer downgraded the stock to "Perform" from "Outperform." Such a rating reduction by a major financial firm typically signals diminished confidence in the company's near-term growth prospects and can trigger immediate selling pressure.

This downgrade follows the company's recent financial report which missed analyst expectations for both revenue and earnings per share. Furthermore, the guidance provided for the upcoming fiscal year fell below market projections, adding to investor concerns about the company's operational performance and future outlook.